ClinicalTrials.gg
RecruitingNCT06215378ATLANTIS-ProtaUpdated Aug 22, 2025

Antagonization of Heparin With Protamine Sulfate After TAVI

A Phase 3 interventional study of Antagonization of heparin with protamine sulfate in Aortic Valve Stenosis and Heart Valve Diseases, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
940
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Aortic Valve Stenosis with a site in France — 22 open to participants now, 34 under way, 2 of them phase 3. Aortic Valve Stenosis · France.

Planned enrollment
13th of 69
940 · median 186
Started
2025
with 4 others
Phase 3
7 of 131
2 open now
Primary completion
2027-03
later than 19 of 33 live
Registered
120th of 131
by date
Lead sponsor
8 of 131
Assistance Publique - Hôpitaux de Paris

Among the 131 studies in Aortic Valve Stenosis with a site in France, this one is the 13th largest by planned enrollment of the 69 interventional ones that give a count, is one of 5 that started in 2025, is one of 7 in phase 3, reaches primary completion later than 19 of the 33 other live ones, and was the 120th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

22 of the 131 studies in Aortic Valve Stenosis with a site in France are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Aortic Valve Stenosis with a site in France, or all of them as a file.
02

Study summary

Transcatheter aortic valve replacement (TAVR) is now the first therapeutic option offered to high and intermediate risk patients with symptomatic aortic stenosis but even to low-risk, when the aortic valve is tricuspid and the transfemoral approach is suitable. Vascular and bleeding complications are the most frequent procedure-related unwanted events associated with increased short-term morbidity and mortality. Selection of the appropriate vascular access site and pre-closing devices as well as stent implantation mitigate these complications.

ACT-guided heparin reaching a target of 300 seconds or more is recommended prior to the placement of the guiding sheath in the common femoral artery. Protamine sulfate is the heparin antidote, which antagonizes 100% of its anti-IIa activity and 60% of its anti-Xa activity. Reversal of heparin using protamine sulfate is recommended for transapical and complicated transfemoral aortic valve placement.However, there is a great heterogeneity of protamine use in daily practice and supportive evidence for the prevention of bleeding complications as well as its safety is lacking. In addition, the radial approach for the second vascular access is more commonly used as well as the use of echo-guided femoral puncture further questioning reversal of heparin when the procedure has been successfully completed without overt bleeding complications.

Our study aims to demonstrate the superiority of a strategy of systematic ACT-guided heparin administration followed by systematic antagonization with protamine sulfate over usual of care to reduce in-hospital mortality, vascular/bleeding complications, stroke and transcient ischemic attack, myocardial infarction or red blood cell transfusion, from randomization to hospital discharge

03

Conditions studied

  • Aortic Valve Stenosis
  • Heart Valve Diseases

Keywords

  • TAVI
  • Protamine
  • Heparine
  • Antagonization
  • Aortic stenosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥18 years of age
  • Any patient eligible for transfemoral TAVI, irrespective of the chronic antithrombotic treatment
  • Written
  • Registered at the French social healthcare

Exclusion criteria

Exclusion Criteria:

  • Any major protamine sulfate exposure defined as a history of severe pulmonary hypertension, acute pulmonary edema or history of bronchospasm related to protamine sulfate administration
  • Known allergy to protamine sulfate
  • to protamine sulfate including protamine contained as an in NPH [Neutral Protamine Hagedorn] insulin, known protamine or protamine-heparine complex antibodies
  • Non-femoral approach for the TAVI procedure
  • Protamine sulfate exposure within 24h of randomization
  • Fish allergy
  • Mechanical valves
  • For men: Sterile or Vasectomy
  • Women of
  • Pregnancy and breast feeding women
  • Contemporaneous enrolment in an interventional clinical trial
  • Patient under guardianship or curatorship
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
940 participants (estimated)

Study arms

  • Experimental
    Systematic heparine antagonization with protamine sulphate

    Complete reversal of the Heparin administered during the TAVI achieved through the infusion of a protamine solution until the ACT returns to its baseline level.

    Drug: Antagonization of heparin with protamine sulfate

  • No intervention
    No Systematic heparine antagonization with protamine sulphate

    No administration of protamine solution unless a participant encounters a bleeding event requiring a surgery or percutanous intervention.

Interventions

  • DrugAntagonization of heparin with protamine sulfate

    A systematic use at the end of procedure of Protamine Sulfate for antagonization of heparine.1 mg of protamine sulfate neutralizes approximately 100 heparin unit. To be administered in slow infusion (10 min) not exceeding 50mg of protamine sulfate to reverse 100% of the anti-IIa activity of heparin sodium. If the ACT is not back to the baseline value after the end of this infusion, additional doses of protamine should be performed depending on the ACT value to obtain complete antagonization of anti-IIa activity of heparin sodium

06

What researchers measure

Primary outcomes

  1. Composite of ischemic and bleeding events

    The primary endpoint is defined as the first occurrence, of any event of the composite of all-cause mortality, type 2, 3 or 4 bleeding, major or minor vascular complications, stroke or TIA, myocardial infarction or any redblood transfusion. The primary endpoint will be blindly determined by a clinical event committee according to the valve Academic Research Consortium-3 (VARC-3 classifications)

    Time frame: From procedure to hospital discharge (or at 30 days whichever comes first)

Secondary outcomes

  1. In hospital stay

    Assessment of length of in-hospital stay in days post TAVI procedure

    Time frame: From procedure to hospital discharge, assessed up to 30 days

  2. Bleeding complication

    Assessment of the occurrence of: * Type 2, 3 or 4 bleeding according to the VARC 3 criteria or any red blood cell transfusion of minor or vascular complications. * Type 2, 3 or 4 bleedings or red blood cell transfusion. * Any red blood cell transfusion * Type 2, 3 or 4 bleedings

    Time frame: From procedure to hospital discharge (or at 30 days whichever comes first)

  3. Assessement of interaction

    Assessment of an interaction in the impact of systematic antagonization according to the use or not of an echo-guided femoral puncture and/or arterial radial access. These subgroups are defined at the time of randomization by stratification.

    Time frame: From procedure to hospital discharge (or at 30 days whichever comes first)

  4. Assessement of adverse outcome

    Assessment of the occurrence of: * Death or type 2, 3 or 4 bleedings * Any kidney injury, stage 2 to 4 according to the KDIGO definition * Death, type 2, 3 or 4 bleedings or stroke * Death, VARC 3 type 2-3-4 bleeding or Any red blood cell transfusion, MI or stroke Or TIA * Any myocardial infarction, stroke or TIA * Type 3 or 4 bleeding * Type 2 bleeding * Minor vascular complications * Access site and access related vascular injury according to VARC-3 criteria

    Time frame: From procedure to hospital discharge (or at 30 days whichever comes first)

  5. Assessement of long term adverse outcome

    Assessment of the composite of: Death, stroke, TIA, MI and bleeding VARC type 2 or more as well as each individual endpoint

    Time frame: From procedure 12 months post procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Mar 2027, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2023
First posted
Jan 22, 2024
StartActual
May 25, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06215378
Collaborators
Action Research Group
Responsible party
Sponsor
First posted
Jan 22, 2024
Start date
May 25, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Aug 22, 2025

Study contacts

Paul Dr GUEDENEY, MD
Contact
paul.guedeney@aphp.fr
0184827619 ext. +33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion